Squalene-adjuvanted H7N9 virus vaccine induces robust humoral immune response against H7N9 and H7N7 viruses

Vaccine

Volumn 32, Issue 35, 2014, Pages 4485-4494

  Wu, Chia Ying ^a   Chang, Ching Yuan ^a   Ma, Hsiu Hua ^b   Wang, Chiung Wen ^a   Chen, Yung Tsung ^a   Hsiao, Pei Wen ^c   Chang, Ching Chuan ^a   Chan, Chi Hsien ^a   Liu, Chung Cheng ^a   Chen, Juine Ruey ^a  

^a Adimmune Corporation   (Taiwan)

^b GENOMICS RESEARCH CENTER   (Taiwan)

^c AGRICULTURAL BIOTECHNOLOGY RESEARCH CENTER   (Taiwan)

Author keywords

Adjuvant; H7N7; H7N9; Humoral immune response; Inactivated virus vaccine; Pandemic influenza

Indexed keywords

ALUMINUM HYDROXIDE; INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; PLACEBO; SQUALENE; VIRUS ANTIGEN; VIRUS HEMAGGLUTININ; ADDAVAX; IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; POLYSORBATE; SUBUNIT VACCINE;

ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; CROSS REACTION; DRUG EFFICACY; DRUG FORMULATION; FEMALE; HEMAGGLUTINATION INHIBITION; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; INFLUENZA VIRUS A H7N7; INFLUENZA VIRUS A H7N9; LD 50; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL; VIRION; VIRUS NEUTRALIZATION; ANIMAL; BAGG ALBINO MOUSE; HEMAGGLUTINATION INHIBITION TEST; IMMUNOLOGY; ORTHOMYXOVIRIDAE INFECTIONS; SERODIAGNOSIS;

ADJUVANTS, IMMUNOLOGIC; ALUMINUM HYDROXIDE; ANIMALS; CROSS REACTIONS; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; IMMUNITY, HUMORAL; INFLUENZA A VIRUS, H7N7 SUBTYPE; INFLUENZA A VIRUS, H7N9 SUBTYPE; INFLUENZA VACCINES; MICE, INBRED BALB C; NEUTRALIZATION TESTS; ORTHOMYXOVIRIDAE INFECTIONS; POLYSORBATES; SQUALENE; SURVIVAL ANALYSIS; VACCINES, INACTIVATED; VACCINES, SUBUNIT;

EID: 84904388233     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.06.043     Document Type: Article

References (26)

1. Gao H.N., Lu H.Z., Cao B., Du B., Shang H., Gan J.H., et al. Clinical findings in 111 cases of influenza A (H7N9) virus infection. N Engl J Med 2013, 368:2277-2285.
2. Chang S.-Y., Lin P.-H., Tsai J.-C., Hung C.-C., Chang S.-C. The first case of H7N9 influenza in Taiwan. Lancet 2013, 381:1621.
3. Parry J. H7N9 virus is more transmissible and harder to detect than H5N1, say experts. Br Med J 2013, 346:f2568.
4. Li Q., Zhou L., Zhou M., Chen Z., Li F., Wu H., et al. Epidemiology of human infections with avian influenza A(H7N9) virus in China. N Engl J Med 2014, 370:520-532.
5. Tang R.B., Chen H.L. An overview of the recent outbreaks of the avian-origin influenza A (H7N9) virus in the human. J Chin Med Assoc 2013, 76:245-248.
6. Morens D.M., Taubenberger J.K., Fauci A.S. Pandemic influenza viruses-hoping for the road not taken. N Engl J Med 2013, 368:2345-2348.
7. Zhang Q., Shi J., Deng G., Guo J., Zeng X., He X., et al. H7N9 influenza viruses are transmissible in ferrets by respiratory droplet. Science 2013, 341:410-414.
8. Tharakaraman K., Jayaraman A., Raman R., Viswanathan K., Stebbins Nathan W., Johnson D., et al. Glycan receptor binding of the influenza A virus H7N9 hemagglutinin. Cell 2013, 153:1486-1493.
9. Zhu H., Wang D., Kelvin D.J., Li L., Zheng Z., Yoon S-W., et al. Infectivity, transmission, and pathology of human-isolated H7N9 influenza virus in ferrets and pigs. Science 2013, 341:183-186.
10. Xiong X., Martin S.R., Haire L.F., Wharton S.A., Daniels R.S., Bennett M.S., et al. Receptor binding by an H7N9 influenza virus from humans. Nature 2013, 499:496-499.
11. Richard M., Schrauwen E.J., de Graaf M., Bestebroer T.M., Spronken M.I., van Boheemen S., et al. Limited airborne transmission of H7N9 influenza A virus between ferrets. Nature 2013, 501:560-563.
12. Couch R.B., Patel S.M., Wade-Bowers C.L., Niño D. A randomized clinical trial of an inactivated avian influenza A (H7N7) vaccine. PLoS One 2012, 7:e49704.
13. Cox R.J., Hovden A.O., Brokstad K.A., Szyszko E., Madhun A.S., Haaheim L.R. The humoral immune response and protective efficacy of vaccination with inactivated split and whole influenza virus vaccines in BALB/c mice. Vaccine 2006, 24:6585-6587.
14. O'Hagan D.T. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert Rev Vaccines 2007, 6:699-710.
15. Pellegrini M., Nicolay U., Lindert K., Groth N. Della Cioppa G. MF59-adjuvanted versus non-adjuvanted influenza vaccines: Integrated analysis from a large safety database. Vaccine 2009, 27:6959-6965.
16. Bernstein D.I., Edwards K.M., Dekker C.L., Belshe R., Talbot H.K.B., Graham I.L., et al. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis 2008, 197:667-675.
17. ®-adjuvanted vaccines for seasonal and pandemic influenza prophylaxis. Influenza Other Respir Viruses 2008, 2:243-249.
18. Leroux-Roels I., Borkowski A., Vanwolleghem T., Drame M., Clement F., Hons E., et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007, 370:580-589.
19. Belshe R.B., Frey S.E., Graham I., Mulligan M.J., Edupuganti S., Jackson L.A., et al. Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant. J Infect Dis 2011, 203:666-673.
20. Czajka H., Unal S., Ulusoy S., Usluer G., Strus A., Sennaroglu E., et al. A phase II, randomised clinical trial to demonstrate the non-inferiority of low-dose MF59-adjuvanted pre-pandemic A/H5N1 influenza vaccine in adult and elderly subjects. J Prev Med Hyg 2012, 53:136-142.
21. Atmar R.L., Keitel W.A., Patel S.M., Katz J.M., She D., El Sahly H., et al. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin Infect Dis 2006, 43:1135-1142.
22. Jadhao S.J., Achenbach J., Swayne D.E., Donis R., Cox N., Matsuoka Y. Development of Eurasian H7N7/PR8 high growth reassortant virus for clinical evaluation as an inactivated pandemic influenza vaccine. Vaccine 2008, 26:1742-1750.
23. De Groot A.S., Ardito M., Terry F., Levitz L., Ross T., Moise L., et al. Low immunogenicity predicted for emerging avian-origin H7N9: implication for influenza vaccine design. Hum Vaccine Immunother 2013, 9:950-956.
24. Couch R.B., Decker W.K., Utama B., Atmar R.L., Nino D., Feng J.Q., et al. Evaluations for in vitro correlates of immunogenicity of inactivated influenza a H5, H7 and H9 vaccines in humans. PLoS One 2012, 7:e50830.
25. Ennis F.A., Mayner R.E., Barry D.W., Manischewitz J.E., Dunlap R.C., Verbonitz M.W., et al. Correlation of laboratory studies with clinical responses to A/New Jersey influenza vaccines. J Infect Dis 1977, 136(Suppl):S397-S406.
26. Cueno M.E., Imai K., Tamura M., Ochiai K. Structural differences between the avian and human H7N9 hemagglutinin proteins are attributable to modifications in salt bridge formation: a computational study with implications in viral evolution. PLoS One 2013, 8:e76764.